The group agreed that the future of NMIBC treatment depends on biomarkers that can direct patients toward the therapy most likely to work. The group agreed that treatment selection for ...

NAI plus BCG demonstrates significant disease-specific survival, progression-free survival, and cystectomy avoidance in BCG-unresponsive high-grade papillary-only NMIBC at 36 months. The treatment is ...

Flibanserin (Addyi) is now approved for treating HSDD in postmenopausal women, expanding its previous indication for premenopausal women. The FDA's priority review designation for flibanserin ...

The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...

Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...

FDA clears stapler for use with da Vinci SP surgical system ...

Celeste Kirschner, CAE, MHSA, outlines the most pressing challenges facing independent urology practices today. "I think MRI has really been perhaps the most transformative development in the realm of ...

Hannah Clarke | Authors | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

The PR.21 study found no significant difference in rPFS between 177Lu-PSMA-617 and docetaxel in mCRPC patients. 177Lu-PSMA-617 showed a higher PSA response rate compared to docetaxel, with 36% vs 16% ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...

The ASPIRE trial evaluates the addition of docetaxel to standard hormone therapy and apalutamide in metastatic castration-sensitive prostate cancer. Approximately 1200 participants will be enrolled ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...